Glimestar-PM1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Pioglitazone 15mg, formulated as an extended-release tablet for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, further enhances insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ). The extended-release formulation ensures a sustained therapeutic effect, promoting better patient compliance through once-daily dosing. Glimestar-PM1 is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy with any of the individual components. It is essential to monitor blood glucose levels regularly and adjust the dosage accordingly to minimize the risk of hypoglycemia and other adverse effects. Caution is advised in patients with renal or hepatic impairment, heart failure, or a history of lactic acidosis. This combination therapy offers a multifaceted approach to glycemic management by targeting different pathophysiological defects in type 2 diabetes.